Vineti and Tessa Therapeutics Partner to Expand Global Access to Personalized T Cell Therapies for Solid Tumors

VCBeat (WeChat: vcbeat) learned from foreign media that on November 22, 2018, U.S. time, Vineti, a leading digital record platform focused on personalized treatment, announced a collaborative agreement with Tessa Therapeutics (hereinafter referred to as “Tessa”) to promote and expand personalized cell therapy for solid tumors worldwide.

Image source: Vineti official website

Headquartered in Singapore, Tessa is a biotechnology company focused on clinical research and development in cancer treatment, specializing in cellular immunotherapies for cancer. It is a leading developer of personalized T-cell therapies targeting solid tumors. Vineti, a pioneering healthcare informatics company co-founded by GE and the Mayo Clinic, has launched the first commercial cloud platform designed to scale cell and gene therapies.

Under this agreement, Vineti will support Tessa in establishing promotional channels on its cloud platform and provide commercialization support for the latter’s products currently in clinical development. The goal is to promote Tessa’s therapies worldwide in a safe and effective manner, with a focus on providing Tessa with a digital coding platform to track, integrate, and streamline operations involving personalized treatment approaches and complex logistics chains. Vineti has already partnered with 65 major medical centers to provide technical support to healthcare providers and patients. The company is rapidly expanding its markets in Europe and the Asia-Pacific region.

Tessa’s virus-specific T cell (VST) technology has demonstrated compelling efficacy and an excellent safety profile in cancer treatment. The company is currently conducting a multicenter Phase 3 clinical trial for nasopharyngeal carcinoma, as well as Phase 1 trials for cervical cancer and oropharyngeal cancer. The latter are scheduled to advance to Phase 2 clinical development in 2019. Furthermore, Tessa is leveraging its VST platform to develop a series of preclinical therapeutic solutions targeting major cancers, including liver and lung cancer.

Vineti has launched the first cloud-based software platform designed for cell and gene therapies, enabling the scalable integration of patient-specific personalized treatments into mainstream medicine through secure and efficient methods. Its core principle is to coordinate, manage, integrate, and streamline all key steps and stakeholders involved in complex cell and gene therapy processes, thereby optimizing efficiency from biopharmaceutical suppliers to healthcare providers and ultimately enhancing patients’ treatment journeys.

Vineti is a healthcare informatics company co-founded by GE and the Mayo Clinic, headquartered in California, USA. It has launched the first cloud-based software platform designed for cell and gene therapies. To date, Vineti has raised approximately $47.3 million across two funding rounds from its investors.

Tessa, founded in 2002 and headquartered in Singapore, is a biotechnology company focused on the clinical development of cancer therapeutics. Its scientific vision is to redirect patients’ own potent antiviral immune responses to identify and kill cancer cells. To date, the company has raised $130 million across two rounds of financing.